MODIFICATION OF THE NUCLEOTIDE COFACTOR-BINDING SITE OF CYTOCHROME P450 REDUCTASE TO ENHANCE TURNOVER WITH NADH IN VIVO by Elmore, Calvin Lee
University of Kentucky 
UKnowledge 
University of Kentucky Doctoral Dissertations Graduate School 
2003 
MODIFICATION OF THE NUCLEOTIDE COFACTOR-BINDING SITE 
OF CYTOCHROME P450 REDUCTASE TO ENHANCE TURNOVER 
WITH NADH IN VIVO 
Calvin Lee Elmore 
University of Kentucky, clelmo2@uky.edu 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Elmore, Calvin Lee, "MODIFICATION OF THE NUCLEOTIDE COFACTOR-BINDING SITE OF CYTOCHROME 
P450 REDUCTASE TO ENHANCE TURNOVER WITH NADH IN VIVO" (2003). University of Kentucky 
Doctoral Dissertations. 467. 
https://uknowledge.uky.edu/gradschool_diss/467 
This Dissertation is brought to you for free and open access by the Graduate School at UKnowledge. It has been 
accepted for inclusion in University of Kentucky Doctoral Dissertations by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
 
 
 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
 
 
 
Calvin Lee Elmore 
 
 
 
 
 
 
The Graduate School 
University of Kentucky 
2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MODIFICATION OF THE NUCLEOTIDE COFACTOR-BINDING SITE 
 OF CYTOCHROME P450 REDUCTASE TO ENHANCE 
 TURNOVER WITH NADH IN VIVO 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
A dissertation submitted in partial fulfillment of the 
 requirements of the degree of Doctor of Philosophy in  
The Graduate School  
at the University of Kentucky 
 
By 
 Calvin Lee Elmore 
Lexington, Kentucky 
Director:  Dr. Todd D. Porter, Associate Professor, Pharmaceutical Sciences 
2003 
Copyright © Calvin Lee Elmore 2003 
 
 
  
 
 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
 
 
 
MODIFICATION OF THE NUCLEOTIDE COFACTOR-BINDING SITE 
 OF CYTOCHROME P450 REDUCTASE TO ENHANCE  
TURNOVER WITH NADH IN VIVO 
 
 NADPH-cytochrome P450 reductase is the electron transfer partner for the 
cytochromes P450, heme oxygenase, and squalene monooxygenase, and is a 
component of the nitric oxide synthases and methionine synthase reductase.  P450 
reductase shows very high selectivity for NADPH and uses NADH only poorly.  
Substitution of tryptophan 677 with alanine (W677A) has been shown by others to yield 
a 3-fold increase in turnover with NADH, but profound inhibition by NADP+ makes the 
enzyme unsuitable for in vivo applications.  In the present study site-directed 
mutagenesis of amino acids in the 2'-phosphate-binding site of the NADPH domain, 
coupled with the W677A substitution, was used to generate a reductase that was able 
to use NADH efficiently in vivo without inhibition by NADP+.  Of 11 single, double, and 
triple mutant proteins, two (R597M/W677A and R597M/K602W/W677A) showed up to a 
500-fold increase in catalytic efficiency (kcat/Km) with NADH.  Inhibition by NADP+ was 
reduced by up to four orders of magnitude relative to the W677A protein and was equal 
to or less than that of the wild-type reductase.  Both proteins were 2- to 3-fold more 
active than wild-type reductase with NADH in reconstitution assays with cytochrome 
P450 1A2 and with squalene monooxygenase.  In a recombinant cytochrome P450 2E1 
Ames bacterial mutagenicity assay the R597M/W677A protein increased the sensitivity 
to dimethylnitrosamine by approximately 2-fold, suggesting that the ability to use NADH 
 
afforded a significant advantage in this in vivo assay.  In addition to providing a valuable 
tool for understanding the determinants of nucleotide cofactor specificity in this and 
related enzymes, these mutants might also lend themselves to creation of 
bioremediation schemes with increased enzymatic activity and robustness in situ, as 
well as cost-effective reconstitution of enzyme systems in vitro that do not require the 
use of expensive reducing equivalents from NADPH. 
 
        C. Lee Elmore 
  
        April 25, 2003 
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CHAPTER ONE 
INTRODUCTION 
 
Cytochrome P450 Reductase, a Unique Flavoprotein 
 
 NADPH-cytochrome P450 reductase (EC 1.6.2.4) is the electron-donating 
partner for the cytochromes P450, squalene monooxygenase, and heme oxygenase, 
and is a component of the nitric oxide synthases and methionine synthase reductase.  
P450 reductase is essential to cholesterol and steroid synthesis, and its importance is 
underscored by the developmental abnormalities and embryonic lethality observed in 
P450 reductase-null mice (Shen, O'Leary et al. 2002).  P450 reductase contains one 
mol of flavin adenine dinucleotide (FAD) and one mol of flavin mononucleotide (FMN) 
per mol of enzyme.  Reduced nicotinamide adenine dinucleotide phosphate (NADPH) 
transfers two electrons as a hydride ion to the FAD of the enzyme, and FMN then 
accepts single electrons from the FAD and acts as the exit point to the protein acceptor 
such as the cytochromes P450. 
 
Structure of Cytochrome P450 Reductase 
 
 P450 reductase is a multi-domain protein with the FAD and NADP(H) domains 
homologous with ferredoxin-NADP+ reductase and the FMN domain homologous with 
flavodoxin, suggesting that P450 reductase was formed from an ancestral gene fusion 
event (Porter and Kasper 1986; Porter 1991).  A fourth connecting domain acts as a 
hinge to orient the two flavin-containing domains for electron transfer, and an NH2-
terminal membrane-binding domain anchors the protein to the cytosolic side of the 
endoplasmic reticulum and the nuclear membrane.  The three-dimensional structure 
was determined by X-ray crystallography, and superbly illustrates the modular structure 
of this unique flavoprotein (Wang, Roberts et al. 1997).  Figure 1.1 illustrates, in cartoon 
format, the multi-domain structure of the enzyme.  The NADP(H) domain adopts the 
typical dinucleotide fold structure consisting of alternating α–helices and β–strands, with 
the nicotinamide cofactor binding in a cleft between the FAD and NADP(H) domains.  
2 
While the adenine portion of the dinucleotide cofactor was tightly bound in 
crystallographic preparations, the nicotinamide portion was found to adopt multiple 
conformations.  However, none of the nicotinamide conformations were representative 
of the catalytic form of the enzyme.  First, the distances between nucleotide and FAD 
were too great and more interestingly, access to the flavin was blocked by the 
penultimate C-terminal residue, a tryptophan (Wang, Roberts et al. 1997).  Several 
drawings based on the three-dimensional structure of P450 reductase are included in 
Figs. 1.2-1.4 and illustrate the nucleotide binding pocket of the protein as well as the 
key residues which are likely to determine nucleotide cofactor specificity. 
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FIGURE 1.1 Cartoon illustrating the multi-domain structure of NADPH-cytochrome 
P450 reductase. 
 
FAD
FMN
Membrane
anchor
NADPH
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FIGURE 1.2 Space-filling drawing of NADPH-cytochrome P450 reductase with 
FAD and FMN domains noted.  The NADPH-binding region is outlined with the 
adenine portion of the dinucleotide partially filling the pocket.  The nicotinamide 
portion of NADPH adopted multiple conformations in the crystal structure and is 
not shown.  The figure is adapted from Wang et al (Wang, Roberts et al. 1997). 
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FIGURE 1.3 Ribbons diagram representation of NADPH-cytochrome P450 
reductase with bound FAD, FMN, and the adenine portion of NADPH.  This figure 
was adapted from Wang et al. (Wang, Roberts et al. 1997). 
 
 
 
FMN 
FAD 
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FIGURE 1.4 Diagram of the NADPH-binding domain of P450 reductase.  Residues 
mutated in these studies are labeled.  Notice that serine 596, arginine 597, and 
lysine 602 form a binding pocket for the 2'-phosphate of NADPH.  Also, 
tryptophan 677 is shown in a conformation that would block productive binding 
of the nicotinamide portion of NADPH.  The figure is adapted from Wang et al 
(Wang, Roberts et al. 1997). 
 
 
 
 
 
Enzymology of Cytochrome P450 Reductase 
 
 Cytochrome P450 reductase donates reducing equivalents from NADPH to redox 
partners such as the cytochromes P450.  Two electrons are transferred from NADPH 
FMN
FAD 
S596
K602
W677
R597
Y6042'P
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via hydride transfer to the FAD; FAD transfers single electrons to FMN.  The acceptor 
protein accepts two electrons one-at-a-time in a two electron reduction.  Human P450 
reductase cycles from the three electron reduced state to the one electron reduced 
state (Figure 1.5), highlighting the importance of redox potentials of the flavins for 
electron transfer.  The reaction was determined by Sem and Kasper to be two-site ping-
pong with cytochrome c (Sem and Kasper 1994).   
 
FIGURE 1.5 Electrons flow into NADPH-cytochrome P450 reductase from NADPH 
by hydride transfer.  The reductase cycles between a three and one electron 
reduced state.  FAD accepts two electrons from NADPH, but FMN acts as a one-
electron donor/acceptor and shuttles single electrons to the target molecule. 
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 In the case of the cytochromes P450, in general, molecular oxygen is split:  one 
oxygen atom is reduced to water, the other used for carbon oxidation.  The general 
P450 reaction scheme is presented in Fig. 1.6, adapted from a review by F. P. 
Guengerich  (Guengerich 2001).  The iron containing heme of P450 is bound to the 
enzyme through four heme nitrogens, and also a cysteine, which causes the 
characteristic absorbance maximum at 450 nm.  Histidine ligand-heme proteins (e.g. 
hemoglobin) have an absorbance maximum of 420 nm.  In the absence of substrate, 
the heme iron is in the ferric state.  Substrate binding triggers a one electron reduction 
from P450 reductase, leading to the formation of ferrous iron.  Molecular oxygen then 
becomes bound to the ferrous iron center.  A second, one electron reduction from P450 
reductase leads to splitting of the oxygen-oxygen bond, with the release of one atom as 
water.  The remaining oxygen-iron complex forms the reactive FeO3+ which is able to 
oxidize substrate. 
 
8 
FIGURE 1.6 The reaction cycle of the typical cytochrome P450 cycle.  NADPH-
cytochrome P450 reductase donates electrons in a two electron reduction of the 
heme of P450.  Molecular oxygen is split, one atom is utilized to oxidize substrate, 
and the other atom is reduced to water.  Figure adapted from an excellent review 
of cytochrome P450 metabolism by F. P. Guengerich.  (Guengerich 2001) 
 
 
 
 The physiologically relevant nucleotide cofactor for cytochrome P450 reductase 
is NADPH.  The reductase can be driven by non-physiological concentrations of NADH 
in the millimolar range, while NADPH facilitates catalysis at low micromolar levels.  The 
ratio between the Km with NADPH versus the Km with NADH is higher for P450 
reductase than that of other NADPH specific enzymes, see Fig. 1.7 (Sem and Kasper 
1993).  Understanding the nature of P450 reductase’s high selectivity for NADPH is one 
of the primary aims of this research.  The only chemical difference between NADPH and 
NADH is the presence of a 2'-phosphate on the adenine ribose, as shown in Figs. 1.8 
and 1.9.  Therefore, this phosphate must be a key factor in determining specificity 
9 
between the two nucleotides.  This must also be true for other enzymes which are 
specific for the nicotinamide adenine dinucleotide cofactors.  These nucleotides are 
generally utilized differentially by cells; the NADH pool is important for catabolism and 
the NADPH pool for anabolic reactions.    
 
FIGURE 1.7 NADPH-cytochrome P450 reductase maintains high selectivity for 
NADPH over NADH (Sem and Kasper 1993).  Even among similar NADPH-utilizing 
enzymes (Arnon 1965; Cove 1967; Huang, Appleman et al. 1990; Scrutton, Berry 
et al. 1990), P450 reductase has unusually high specificity for the phosphate-
containing nucleotide. 
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FIGURE 1.8 NADPH and NADH differ only in the presence of a phosphate on the 
number two carbon of the adenine ribose.  In NADH this moiety is a hydroxyl 
group. 
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FIGURE 1.9 A space-filling drawing of NADPH.  The 2'-phosphate creates a unique 
shape and charge for nucleotide recognition. 
 
 
 
Regulation of Cytochrome P450 Reductase 
 
 While there are many isoforms of cytochrome P450 enzymes in mammals, there 
is only one protein responsible for donating electrons, NADPH-cytochrome P450 
reductase.  P450 reductase is universally expressed, though the highest levels are 
found in the liver.  While many of the cytochromes P450 are highly inducible, P450 
reductase is independently regulated and is present at basal levels.  The single 
reductase gene is localized on human chromosome 7, and, like other house-keeping 
genes, the promoter region lacks TATA and CCAAT boxes (O'Leary, Beck et al. 1994).  
The GC-rich promoter region does contain nine consensus sequences for the SP1 
transcription factor, however it appears that the proximal two sites are most important 
for transcription, but are not absolutely required  (O'Leary, McQuiddy et al. 1996).  
Furthermore, a thyroid response element was discovered by O’Leary and others 
(O'Leary, Li et al. 1997).  Indeed, hypophysectomy of adult male rats produces an 80-
85% decrease in liver P450 reductase protein levels, causing a drop of up to 85% in the 
12 
level of P450 reductase activity, likely due to a decrease in observed P450 reductase 
mRNA levels (Ram and Waxman 1992).     
 
Knock-out Studies 
  
 Basic questions regarding the importance of functional P450 reductase were 
addressed in recent reports that describe both the complete and conditional-hepatic 
knock-out of the P450 reductase gene in mouse.  Complete loss of the P450 reductase 
gene results in embryonic lethality at day 11 of gestation, further characterized by 
developmental abnormalities in the neural tube, cardiac, eye and limb (Shen, O'Leary et 
al. 2002).  These results emphasize the important role P450 reductase plays in 
providing electrons to enzymes important for development, including many involved in 
cholesterol synthesis and breakdown, retinoic acid metabolism, and heme catabolism. 
Conditional deletion of the P450 reductase gene in the liver of adult mice by the Cre/lox 
system leads to an impaired ability to both generate cholesterol and to eliminate it 
through bile acid synthesis, and is characterized by elevated hepatic lipids, reduced 
serum cholesterol levels and reduced bile flow.    Furthermore, hepatic-null reductase 
mice completely lost microsomal P450 function in the liver, resulting in a five-fold 
induction of P450 enzymes with essentially no activity.  Phenobarbital administration in 
hepatic reductase-null mice induced prolonged sleep at a concentration that produced 
no sleep in wild-type animals.  Dosing of acetaminophen led to a 90% drop in hepatic 
glutathione levels and a rise in serum indicators of liver failure in wild-type animals, 
whereas glutathione levels and biomarkers of liver health remained stable in P450 
reductase-null animals.  Surprisingly, hepatic-null mice were able to survive and breed, 
emphasizing the predominant role of the P450 system in xenobiotic metabolism in adult 
liver (Henderson, Otto et al. 2003). 
 
Bioremediation 
 
 A primary goal of this research is to develop mammalian enzyme systems with 
improved activity in bacteria, which could lead to more effective bioremediation 
13 
schemes.  Modification of P450 reductase to use both NADH and NADPH could 
contribute to the effort to develop recombinant P450 systems in bacteria for chemical 
degradation.  Bioremediation is the use of biological agents to break down xenobiotics 
in the environment.  Important factors affecting the potential for successful 
bioremediation include the bioavailability of the target toxicant, subsequent transport 
into cells with access to the appropriate metabolizing enzymes, or, alternatively, the 
secretion of appropriate biodegradation enzymes, and the ability of cells to function 
under in situ environmental conditions (Pieper and Reineke 2000).  Intrinsic chemical 
properties, such as stability of target compounds also play a role (Dua, Singh et al. 
2002).  Nature has provided an enormous number of bacterial species capable of 
degrading waste chemicals.  However, limitations include toxicity to biodegrading 
organisms, low nutrient and oxygen levels in situ, and the lack of appropriate 
metabolizing enzymes for complete degradation.  The latter limitation can be addressed 
with the use of genetically engineered microorganisms.   
 
 Over the last decade, many gene sequences for isoforms of the cytochromes 
P450 have been discovered and published.  Furthermore, many have been expressed 
in bacteria along with P450 reductase to produce enzymatic activity comparable to that 
seen in liver microsomes, see Guengerich et al. for a list (Guengerich, Parikh et al. 
1997).  In addition to bioremediation, applications of these systems include cytochrome 
P450 structure-function analysis, screening of P450 substrates to generate profiles, and 
bacterial mutagenicity assays (Guengerich and Parikh 1997).    
 
 If naturally occurring enzymes fail to provide the necessary enzymatic activity for 
bioremediation, several techniques for improving enzyme turnover and/or chemical 
specificity may be attempted.  These methods include rational redesign by site-directed 
mutagenesis based on genetic sequence alignments with similar enzymes and/or 
structure data.  Random mutagenesis and gene shuffling, a.k.a. in vitro  gene 
recombination, approaches compliment rational approaches, as long as there is an 
effective screening technique available for sifting through the large numbers of proteins 
generated (Guengerich 1995).     
14 
 
 Ethical issues regarding the introduction of genetically modified microorganisms 
into the environment cloud the future of such tools for in situ bioremediation 
(Guengerich 1995).  However, only the creation of useful remediation tools including 
genetically engineered bacteria will allow these ethical problems to be addressed.  
Additional limitations to the use of genetically altered bacterial strains include the 
expense of monitoring enzyme activity and engineered bacterial growth in situ and the 
possibility of reduced survival rates among genetically modified bacteria (Sayler and 
Ripp 2000).  Monitoring introduced strains can be accomplished by PCR of recombinant 
DNA or the mRNA transcripts (Pieper and Reineke 2000) or through bioluminescence 
approaches (Dua, Singh et al. 2002).      
 
Recombinant Cytochrome P450/Cytochrome P450 Reductase Systems  
 
 While expression of mammalian P450/reductase systems in bacteria has been 
shown to be a valuable research tool and has promise as a tool for biodegradation 
(Guengerich 1995), enzyme activity in recombinant bacterial systems appears to be 
limited by glucose availability (Shet, Fisher et al. 1997).  One explanation for this might 
be that the generation of NADPH is largely dependent on the glucose shunt pathway, 
which is operative primarily in high glucose environments.  Supporting this hypothesis 
are data from Bochner and Ames (Bochner and Ames 1982) that indicate that bacterial 
NAD(H) levels exceed NADP(H) levels by approximately 4:1.  To address the 
hypothesis that heterologously expressed P450 systems in bacterial cells are limited by 
the availability of NADPH, I constructed a series of reductase proteins designed to use 
NADH more efficiently.  Specific mutations in the nicotinamide cofactor 2'-phosphate-
binding site were generated based on the crystal structure of the reductase from rat 
(Djordjevic, Roberts et al. 1995; Wang, Roberts et al. 1997), and from sequence 
alignments of rat cytochrome P450 reductase (Porter and Kasper 1985) with other 
NADPH- and NADH-specific reductases including spinach ferredoxin-NADP+ reductase 
(Karplus, Daniels et al. 1991), nitrate reductases from Neurospora crassa (NADPH) 
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(Okamoto, Fu et al. 1991), and corn (NADH) (Hyde and Campbell 1990), and NADH-
cytochrome b5 reductase (Yubisui, Naitoh et al. 1987), as shown in Fig. 1.10.  
 
FIGURE 1.10 A sequence alignment between NADPH-cytochrome P450 reductase 
and two related NADPH-specific enzymes along with two related NADH-specific 
enzymes. 
 
 
 
 The functions of these amino acids have been studied previously in cytochrome 
P450 reductase, as well as in the cytochrome P450 reductase homologues nitrate 
reductase and ferredoxin-NADP+ reductase.  For example, studies by Sem and Kasper 
(Sem and Kasper 1993) have shown that arginine 597 of P450 reductase from rat plays 
a critical role in binding the 2'-phosphate of NADPH, and thereby discriminating 
between NADPH and NADH; substitution of this residue with methionine produced a 
reductase with a greater than 100-fold higher Km value for NADPH, while the kcat for 
NADPH remained at a level comparable to wild-type.  The kcat and Km values for NADH 
were similar between wild-type and the Arg597Met substitution (Sem and Kasper 1993).  
However, substitution of serine or threonine for arginine 922 of NADPH-nitrate 
reductase from Neurospora crassa, which corresponds to arginine 597 of P450 
reductase, was shown by Shiraishi et al. to be unable to significantly alter the specific 
activity (µmol/min) with either NADPH or NADH  (Shiraishi, Croy et al. 1998).    This 
indicates a fundamental difference in the amino acid residues that these two proteins 
utilize to bind nucleotide cofactor.  Mutation of arginine 931 to glutamine in nitrate 
reductase, which corresponds to lysine 602 of P450 reductase, led to a decrease in 
NADPH specific activity (µmol/min) and an increase in NADH specific activity 
16 
(µmol/min); catalytic constants were not reported for this protein (Shiraishi, Croy et al. 
1998).  Substitution of aspartic acid for serine 921 in nitrate reductase had a large effect 
on cofactor specificity, leading to 2% of wild-type specific activity (µmol/min) with 
NADPH, but 15-fold greater specific activity (µmol/min) with NADH versus wild-type 
(Shiraishi, Croy et al. 1998).  These changes in specific activity were correlated with the 
decrease in the catalytic efficiency (kcat/Km) for NADPH and an increase for NADH for 
that protein.  Double substitution of S921D/R931S in nitrate reductase led to the 
greatest switch in cofactor specificity, greater than 73,000-fold compared to wild type 
(kcat/Km; NADPH/NADH; wild-type/mutant), but improved the catalytic efficiency 
(kcat/Km) versus wild-type with NADH by only 2.5-fold (Shiraishi, Croy et al. 1998).   
 
 Similar studies have been carried out in ferredoxin-NADP+ reductase from 
spinach, a closely related flavoprotein involved in NADPH production.  Lysine 244 of 
ferredoxin-NADP+ reductase, which corresponds to lysine 602 in P450 reductase, was 
mutated to glutamine, increasing both the Km and the kcat with NADPH (Aliverti, 
Lubberstedt et al. 1991), while NADH activity was not studied in this protein.  These 
comparisons indicate that although high sequence homology exists in the 2'-phosphate 
binding regions of these closely related proteins, it is likely that three-dimensional amino 
acid arrangements ultimately determine the function these residues serve.  
  
 Substitutions of the C-terminal tyrosine in ferredoxin-NADP+ reductase from pea  
produced similar results to the W677A substitution with cytochrome P450 reductase 
presented by Döhr et al. (Dohr, Paine et al. 2001), i.e. a decrease in Km and increase in 
kcat for NADH (Orellano, Calcaterra et al. 1993), but lower Km and kcat for NADPH 
(Orellano, Calcaterra et al. 1993; Piubelli, Aliverti et al. 2000).  Thus, although the 
phosphate-binding amino acids differ between these proteins, aromatic C-terminal 
residues probably perform a similar function in both enzymes in order to maintain 
selectivity for NADPH over NADH.  Döhr et al (Dohr, Paine et al. 2001) demonstrated 
that tryptophan 677 appears to block access of the nicotinamide portion of the NADPH 
cofactor to the flavin, and proposed that this amino acid plays a role in removal of 
NADP+ after hydride transfer.  This amino acid is suggested to contribute to cofactor 
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specificity by blocking the nucleotide-binding site from both NADPH and NADH:  
NADPH, with higher binding affinity due to a 2'-phosphate-binding pocket, is evidently 
able to displace the tryptophan and form a productive electron-transfer complex, 
whereas NADH cannot bind tightly enough to displace the tryptophan.  Consistent with 
this hypothesis, removal or substitution of W677 greatly increases turnover with NADH, 
but leads to inhibition by NADP+.  I hypothesized that mutations in the 2'-phosphate-
binding site might reduce the affinity of the enzyme for NADP(H) and reduce or prevent 
the inhibition by NADP+.  Several highly conserved residues make up the 2'-phosphate-
binding motif, including serine 596, arginine 597, and lysine 602; the position of these 
amino acids in the NADP(H)-binding domain are shown in Fig. 1.4.  The present studies 
reveal that the combination of 2'-phosphate-binding site mutations with the W677A 
substitution yields a cytochrome P450 reductase that uses NADH without inhibition by 
NADP+.  As any enzyme to be used in in vivo applications such as bioremediation must 
retain activity in a mixed nucleotide environment, this reductase may prove useful in 
such applications. 
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CHAPTER TWO 
GENERATION OF CYTOCHROME P450 REDUCTASE COFACTOR MUTANTS 
 
Introduction to Site-Directed Mutagenesis 
 
 Site-directed mutagenesis is an important technique for protein structure-function 
studies.  It allows selected amino acids in a protein to be replaced with either 
conservative or nonconservative substitutions.  Effects of amino acid substitutions can 
be analyzed after subsequent expression and purification of these altered proteins or 
after expression in intact cells.  Several other tools make site-directed mutagenesis 
studies more relevant and conclusive, including sequence alignments of closely-related 
proteins, computer programs that predict structural motifs and techniques which directly 
determine three-dimensional structure such as X-ray crystallography and NMR. 
 
 To test the hypothesis that NADPH might be limiting in bacterial cells expressing 
a recombinant P450 system in vivo, I needed P450 reductase(s) that use NADH under 
physiologically relevant conditions.  Targeting amino acids outlined in Chapter One, I 
used site-directed mutagenesis to substitute amino acids believed to be important for 
nucleotide cofactor binding and recognition.   
 
Generation of P450 Reductase Mutants 
 
 Site-directed mutagenesis was carried out in either pIN3OR6XHis, a P450 
reductase bacterial expression plasmid in which a 6xhistidine tag was placed at the N-
terminus of the reductase, or in pIN3ER plasmid coexpression vector containing the 
cDNAs for rat P450 reductase and human P450 2E1 (Porter and Chang 1999).  Whole 
plasmid amplification (see Fig. 2.1) was performed as described in the QuickChange™ 
site-directed mutagenesis kit (Stratagene) with changes noted.  Primers were designed 
that contained the desired base changes necessary for the desired amino acid 
substitution (Fig. 2.1; Step 1).  Primers were designed to have a melting temperature 
greater than or equal to 78°C.  Alternatively, the set of primers from above were 
19 
combined with other primers and amplified by PCR to generate a longer primer for 
whole plasmid amplification.  These extended primers generally had a length between 
100 and 500 base pairs and contained the desired base changes.  These longer 
primers were generally more efficient in producing whole plasmid amplification.  PCR 
reactions contained 5-50 ng of plasmid template DNA, 50 pmols of each primer or 2 µL 
of PCR product incorporating mutations, deoxynucleotide triphosphates (dNTPs) (200 
µM), 2.5 units of Pfu Turbo Polymerase (Stratagene), Pfu Turbo Polymerase buffer, and 
double deionized water (ddH2O) to 50 µL total volume.  Ninety-five degrees Celsius was 
used to melt template DNA, ~55°C was used as the annealing temperature, and ~68°C 
was used for extension.  Pfu polymerase generally incorporates dNTPs at a rate of 1-2 
minutes/kilobase of template.  Therefore, for pIN3OR6xHis (~9,500 bp) and pIN3ER 
(~11,000 bp) extension times of 19 and 22 min were used.  Eighteen cycles were 
carried out in a Perkin-Elmer 2400 thermocycler.  Products of amplification were 
visualized on a 1% agarose gel with ethidium bromide.  Ten units of Dpn I were added 
to digest methylated parental template DNA (Step 2).  One to five µL of the reaction 
mixture was transformed into chemically competent E. coli (Step 3).  Clones were 
screened by sequencing. 
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FIGURE 2.1 Mutagenesis by whole plasmid amplification. 
  
 
 
 Subcloning is a method of moving sections of double-stranded DNA from one 
vector to another, as depicted in Fig. 2.2.  I used it rarely because of the ease of whole 
plasmid amplification, but occasionally when I wanted to introduce a mutation into a 
plasmid vector or, more commonly, to combine mutations that were far enough apart on 
their plasmid vector that a unique restriction site was located between the mutations.  
This allowed one mutation to be excised, purified, and ligated into a plasmid vector 
containing the second mutation.  Generally, between 100-1,000 ng of plasmid DNA was 
digested with restriction endonucleases (2-10 U) (Step 1).  These restriction enzymes 
were both compatible in the same buffer, or the DNA was purified to remove buffer and 
a second buffer was added.  Five-prime phosphates were removed from vector DNA to 
prevent religation of incompletely digested plasmid DNA, as follows:  Alkaline 
phosphatase (10 U) was added directly to the original restriction digest and incubated 
for 1 hour at 37°C.  Phosphatase activity was terminated by addition of 2 µL 0.5 M 
1.  PCR 
2.  + Dpn I 
3.  Transformation 
1
2
3
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EDTA followed by incubation at 65°C for 20 min.  Insert DNA was separated by 1% 
agarose gel, and the band was excised with a razor blade (Step 2).  Gel pieces were 
spun in a 0.45 µm nylon membrane centrifugal spin tube (Costar) and collected in 1x 
TAE.   DNA was visualized on a 1% agarose gel to determine quantitation.  
Dephosphorylated vector was then added to insert at a 1:3 molar ratio with ligase (1U) 
and incubated overnight a 4°C (Step 3).  Two µL of the ligation reaction was 
transformed into chemically competent E. coli and positive clones were identified by 
DNA sequencing.      
 
FIGURE 2.2 Mutagenesis by sub-cloning. 
 
 
 
 Mutagenesis by overlap-extension (Fig. 2.3) allows multiple changes to primary 
genetic sequences or the creation of chimeric constructs by targeted splicing of two 
unique DNA sequences to create proteins with new and interesting activities.  Primers 
are designed that incorporate the desired mutations (or the novel DNA to be joined) at 
the five prime ends.  These “inside” primers are combined with “outside” primers to 
1 
1
2
2
31. Digest 
2. Purify fragments
3. Ligate  
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create templates that overlap at positions found in the five prime ends of the “inside” 
primers.  An eight-amino acid substitution was introduced by overlap-extension 
polymerase chain amplification as described (Slack 1998) to generate a reductase with 
the following substitutions:  S596D, R597R, E598A, Q599P, A600E, H601A, K602W, 
and V603D.  Two chimeric proteins were designed, containing the NADH-binding region 
of b5 reductase in place of the NADPH-binding region of P450 reductase.  One chimera 
contained the “linker-arm” of P450 reductase, and was named “OR/b5R-short”.  The 
other chimera contained the connecting region of b5 reductase, and was named 
“OR/b5R-long”.  OR/b5R-short was cloned and confirmed by DNA sequencing, yet 
failed to yield protein sensitive to P450 reductase antibody.  The OR/b5R-long construct 
was designed, but was never completed for expression experiments. All mutations were 
confirmed by sequencing.  
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FIGURE 2.3 Mutagenesis by overlap-extension polymerase chain reaction. 
 
 
 
Purification and Quantitation of Proteins 
 
 With all constructs, a fresh colony was selected for protein expression and grown 
overnight in LB media at 37°C.  Overnight culture was used to inoculate up to 6 liters of 
Terrific Broth at 37°C followed by the addition of 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) when the O.D.600 reached 0.8; culture was continued 
1.  PCR (primers A+B/ C+D) 
2.  PCR (primers A & D only)  
3.  Digest 
4.  Ligate 
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overnight at 30°C with shaking (125 rpm).  Cells were harvested by centrifugation and 
the membrane fraction was isolated and solubilized as described (Porter and Chang 
1999), omitting the dithiothreitol and 4-methylpyrazole.  Cells were lysed by French 
press in buffer consisting of 20 mM KPO4 (pH 8.0) and 50 mM KCl.  The lysate was 
clarified at 10,000 x g, and a second supernatant fraction was obtained by centrifugation 
at 100,000 x g.  The membrane pellet was resuspended in a glass dounce homogenizer 
with a type B pestle in 5 mL of 10 mM Tris-Acetate (pH 8.0) and 20% glycerol.  
Solubilization of membranes was carried out on ice with stirring by addition of Triton X-
100 dropwise to 1%.  Solubized membranes were then clarified at 100,000 x g and the 
supernatant used for affinity purification.     
 
 Wild-type P450 reductase and mutants were purified by metal affinity 
chromatography using TALON IMAC metal affinity resin (Clontech) as shown 
schematically in Fig. 2.4.  Typically 3 mL of metal affinity resin (1.5 mL column volume) 
in ethanol was added to a 10 mL plastic column (Biorad).  The column was equilibrated 
in twenty bed volumes of column buffer: 300 mM NaCl, 50 mM NaPO4 (pH 8.0), 1% 
Triton X-100, and 10% glycerol.  Solubilized membranes were added to the column and 
recycled several times for maximum binding.  Twenty column volumes of column buffer 
were used to wash away unbound material.  Proteins were eluted in column buffer plus 
150 mM imidazole (pH 8.0), and stored in the same buffer at -20°C.   
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FIGURE 2.4 An illustration of the purification of NADPH-cytochrome P450 
reductase and mutant enzymes. 
 
 
 
Results of Protein Expression/Purification Experiments 
 
 The purified proteins were largely homogeneous, and migrated with a molecular 
weight of 78.5 kDa, as did wild-type reductase (Fig. 2.5); immunoblotting with antibody 
to P450 reductase indicated that the lower molecular weight contaminants were 
predominantly reductase degradation products (Fig. 2.6).  Reductase was quantified by 
boiling to release the flavins and measuring the absorbance at 450 nm using an 
extinction coefficient of 23.5 mM-1 (Vermilion and Coon 1978), see Fig. 2.7. 
 
Purification of Squalene Monooxygenase 
 
 Purification of squalene monooxygenase was performed as described by Laden 
et al. (Laden, Tang et al. 2000).  The cDNA encoding squalene monooxygenase, 
lacking the first 330 base pairs, from human was cloned previously (Laden, Tang et al. 
2000) into the pTYB4 expression vector, part of the IMPACT T7 System (Clontech) 
which expresses the enzyme along with an intein protein splicing element from yeast 
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and a chitin binding domain.  Bacterial cells were lysed by French press in buffer 
containing 20 mM Tris-HCl (pH 7.4), 500 mM NaCl, 0.1 mM EDTA, and 0.1% Triton X-
100, and centrifuged at 12,000 x g.  The supernatant was loaded on a chitin column 
equilibrated in the same buffer.  Following washing by 20 bed volumes of buffer, the 
column was incubated with buffer containing 30 mM β-mercaptoethanol overnight at 
4°C.  Squalene monooxygenase was eluted and buffer changed to 20 mM Tris-HCl (pH 
7.4), 0.1% Triton X-100 by centrifugal dialysis and stored at -80°C.  Enzyme was 
quantified with the Coomassie Plus Protein Assay Reagent Kit (Pierce). 
  
FIGURE 2.5 Sodium dodecyl sulfate - polyacrylamide gel electrophoresis of P450 
reductase mutants.  Affinity-purified reductase proteins were fractionated on an 
8.75% polyacrylamide gel and stained with Coomassie blue.  Lane 1, molecular 
mass standards at 221, 133, 93, 67, 56, 42, and 28 kDa; 2, wild-type reductase; 3, 
S596D; 4, R597M; 5, K602W; 6, SD/WA; 7, SD/KW; 8, W677A; 9, RM/WA; 10, 
KW/WA; 11, 8 amino acid substitution; 12, RM/KW; 13, RM/KW/WA; and 14, 
SD/WA. 
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FIGURE 2.6 Western blots of P450 reductase mutants.  Lane 1, molecular mass 
standards at 221, 133, 93, 67, 56, 42, and 28 kDa; 2, wild-type reductase; 3, S596D; 
4, R597M; 5, E598A; 6, K602W; 7, molecular mass standards; 8, SD/RM; 9, SD/KW; 
10, W677A; 11, RM/WA; 12, KW/WA. 
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FIGURE 2.7 Flavin spectra of wild-type P450 reductase and mutant proteins. 
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A Comparison between Native Cytochrome P450 Reductase and the 6x-histidine 
Tagged P450 Reductase Construct 
 
 A 6x-histidine tag allows easy, often single-step, column-affinity purification of 
proteins.  However, the addition of six additional histidine residues at the N- or C-
terminus may alter protein function.  Many newer 6x-histidine tag vectors allow the 
removal of the 6x-histidine tag after affinity purification using a thrombin-cleavage site.  
However, this technique invariably yields proteins with additional non-native amino 
acids at the cleavage site.  In order to address this concern with 6x-histidine tagged 
P450 reductase clones, aniline hydroxylation experiments were carried out with wild-
type and 6x-histidine tagged P450 reductases with cytochrome P450 2E1.  Reductase 
concentrations were varied, with all other variables held constant, in order to generate 
Km and Vmax numbers for the two proteins.  Results of these experiments are shown in 
Table 2.1.    
 
 Cytochrome P450 reductase was purified by 2'5'-adenosine diphosphate agarose 
affinity chromatography.  Wild-type proteins were eluted in 50 mM Tris (pH 7.7), 
containing 0.1 mM EDTA, 10% glycerol and 2 mM 2'-adenosine monophosphate.  Wild-
type reductase was quantified by boiling an aliquot and measuring the flavin 
absorbance at 450 nm.  6x-histidine tagged reductase protein was purified as described 
in detail earlier in this chapter.  Cytochrome P450 2E1 protein from rabbit was 
expressed in E. coli.  Membranes were solubilized in octyl-glucoside detergent.  
Proteins were changed into phosphate buffer (pH 7.4) containing 1 mM EDTA and 20% 
glycerol.  Cytochrome P450 2E1 was quantified by carbon monoxide difference spectra 
measuring heme at 450 nm.  Aniline hydroxylation assays contained 10-150 pmols 
reductase, 50 pmols P450 2E1, 1 mM NADPH, and 2.5 mM aniline in the phosphate 
buffer described above.  Reactions were initiated by addition of NADPH and were 
incubated at 37°C for 0, 15 and 30 minutes to determine reaction rates.  para-
Aminophenol production was measured as an increase in absorbance at 630 nm using 
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an HP 8453 spectrophotometer.  Michaelis-Menten kinetic constants were determined 
using GraphPad Prism 3.   
 
 These enzyme assays show that wild-type cytochrome P450 reductase and the 
6x-histidine tagged reductase are not statistically different in their ability to stimulate the 
hydroxylation of aniline to para-aminophenol.  Additionally, during purification, both wild-
type and 6x-histidine tagged reductase were found to be inserted into bacterial 
membranes, suggesting the N-terminal 6x-histidine tag did not alter the enzyme 
conformation significantly enough to alter the ability of the N-terminal membrane binding 
domain to function correctly.  Therefore, 6x-histidine tagged P450 reductase is 
considered to be functionally the same as wild-type for these experiments.    
 
TABLE 2.1 A comparison between wild-type and 6x-histidine tagged reductases.  
Kinetic constants derived from reductase-supported hydroxylation of aniline by 
P450 2E1, in vitro.  Values represent best fits ± S.D. 
 
 
Mutant Km (nM reductase) Vmax (nmols p-AP/hr)
WT 22.6 ± 3.0 17.4 ± 0.8
6x-histidine Tag 14.9 ± 3.8 15.2 ± 1.0  
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CHAPTER THREE 
ACTIVITY ANALYSIS OF CYTOCHROME P450 REDUCTASE 
 MUTANTS WITH CYTOCHROME C 
 
Introduction to Cytochrome c Reductase Activity Assays 
 
 P450 reductase proteins with altered cofactor specificity were evaluated with the 
non-physiological electron acceptor cytochrome c.  Michaelis-Menten kinetic constants 
were determined with each enzyme.  Comparisons between Km, kcat and catalytic 
efficiency (kcat/Km) allowed a means of objectively evaluating the effects of amino acid 
substitutions.  Cytochrome c is inexpensive, stable and readily accepts electrons from 
P450 reductase.  The rate of reduction of the bound heme of cytochrome c can be 
measured at 550 nm.  
 
Steady State Kinetics with Cytochrome c 
 
 Km and kcat determinations were carried out with 60 µM cytochrome c from horse 
heart (Sigma) in 100 mM Tris, pH 8.0 with an ionic strength of 0.75 M with KCl.  
Reactions were started by the addition of nucleotide cofactor (NADPH or NADH) and 
were monitored for 40 seconds at room temperature on an HP 8453 spectrophotometer 
(Hewlett-Packard), following the absorbance change at 550 nm.  An extinction 
coefficient of 21.1 mM-1 was used to quantitate cytochrome c reduction (Vermilion and 
Coon 1978).  Catalytic constants were estimated by non-linear regression using Prism 
(GraphPad Prism 3). 
 
Results of Cytochrome c Reductase Assays 
 
 I generated mutants of cytochrome P450 reductase that have decreased 
specificity for the physiological cofactor NADPH.  These mutants fall into three 
categories:  those containing mutations in the 2'-phosphate-binding region of NADPH; a 
single mutant in which tryptophan 677, which is positioned directly opposite of the FAD 
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isoalloxazine ring, is replaced with alanine; and double and triple combinations of these 
two.  As expected, single and double substitutions in the 2'-phosphate-binding region 
yielded proteins with greatly reduced catalytic efficiency (kcat/Km) with NADPH (Table 
3.1).  A comparison of catalytic constants of P450 reductase proteins is shown in Figs. 
3.1-3.4.  The R597M, S596D, K602W, and R597M/K602W proteins showed a 40- to 
13,000-fold increase in the Km for NADPH as compared to wild-type with cytochrome c 
as the electron acceptor, with the K602W substitution having the least effect on Km and 
the S596D mutation producing the highest Km.  Of these mutants, the S596D showed 
the most profound decrease in the kcat with both NADPH and NADH, indicating an 
overall detrimental effect on electron transfer; all of the mutants containing S596D had 
little or no activity with either cofactor.  Proteins with the R597M substitution (R597M 
and R597M/K602W) maintained turnover numbers with NADPH and NADH that were 
comparable to that of the wild-type enzyme, whereas the K602W mutation decreased 
turnover with both cofactors in the absence of the R597M substitution.  As an alternative 
to individual substitutions, the segment from S596 to V603 (8 amino acids) was 
replaced with the corresponding segment from NADH-cytochrome b5 reductase, a 
closely related NADH-dependent flavoprotein (Yubisui, Naitoh et al. 1987).  The 
resulting mutant protein bound flavin but had no observable cytochrome c reductase 
activity.  Considering that this protein bound flavin, the lack of activity was most likely 
due to alterations of the secondary structure of the 2'-phosphate binding pocket, such 
that productive nucleotide binding was lost. 
 
 The W677A mutant retained only 1.2% of wild-type activity (kcat) with NADPH, 
while the Km for NADPH remained similar to wild-type when assayed with cytochrome c.  
In contrast, the W677A mutant had a kcat with NADH that was approximately 3-fold 
higher than that of wild-type with NADH, while the Km of NADH decreased by 
approximately 250-fold.  The W677A enzyme also showed the most profound change in 
NADH catalytic efficiency with a greater than 700-fold increase versus wild-type.  
Coupled with a decrease in catalytic efficiency with NADPH of 74-fold, it is apparent that 
this single amino acid contributes remarkably to cofactor specificity for NADPH versus 
NADH in wild-type P450 reductase.  
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 Proteins containing altered 2'-phosphate-binding domains and W677A 
substitution showed kinetics resembling the W677A mutation alone.  However, the Km 
for NADPH was significantly increased compared to wild-type in the K602W/W677A, 
R597M/W677A, and R597M/K602W/W677A proteins by 1.5, 2.4, and 54-fold, 
respectively.  With NADH, conversely, the Km values for these proteins remain similar to 
the W677A alone.  Turnover numbers with the combined substitutions with NADH are 
lower than the W677A enzyme.  However with the R597M/W677A and 
R597M/K602W/W677A proteins, kcat values remain equal to or greater than wild-type 
with NADH.  With NADPH, a 4-, 7-, and 43-fold decrease in kcat values is seen with the 
R597M/K602W/W677A, R597M/W677A, and K602W/W677A proteins, respectively.  
 
FIGURE 3.1 Comparison of Km values for 2'-phosphate-binding mutant reductase.  
ND indicates no detectable activity.  WT, wild-type P450 reductase; SD, 
Ser596Asp; RM, Arg597Met; KW, Lys602Trp. 
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FIGURE 3.2 Comparison of Km values for mutant reductases containing the 
Trp677Ala substitution.  ND indicates no detectable activity. .  WT, wild-type P450 
reductase; SD, Ser596Asp; RM, Arg597Met; KW, Lys602Trp; WA, Trp677Ala; 
R/K/W, Arg597Met/Lys602Trp/Trp677Ala. 
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FIGURE 3.3 Comparison of kcat values for 2'-phosphate-binding mutant 
reductases.  ND indicates no detectable activity.  WT, wild-type P450 reductase; 
SD, Ser596Asp; RM, Arg597Met; KW, Lys602Trp. 
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FIGURE 3.4 Comparison of kcat values for mutant reductases containing the 
Trp677Ala substitution.  ND indicates no detectable activity.  WT, wild-type P450 
reductase; SD, Ser596Asp; RM, Arg597Met; KW, Lys602Trp; WA, Trp677Ala; 
R/K/W, Arg597Met/Lys602Trp/Trp677Ala. 
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TABLE 3.1 Catalytic activities of P450 reductase mutants with NADPH and NADH.  The values represent 
best fits ± S.D.    indicates lack of measurable activity. 
 
                    NADPH                                        NADH                    
kcat Km kcat/Km kcat Km kcat/Km NADPH/NADH
Mutant (min-1) (µM) (min-1*µM-1) (min-1) (µM) (min-1*µM-1) (kcat/Km/kcat/Km)
WT 3,280 ± 50 1.6 ± 0.1 2,000 1,210 ± 140 27,600 ± 4,600 0.044 45,000
S596D 140 ± 9 20,600 ± 2,000 0.007 101 ± 6 10,100 ± 1,300 0.010 0.7
R597M 2,980 ± 70 156 ± 10 19 1,350 ± 110 14,100 ± 2,200 0.10 200
E598A 2,390 ± 90 0.8 ± 0.2 3,000 1,250 ± 110 13,200 ± 2,300 0.09 30,000
K602W 1,110 ± 20 64.0 ± 3.2 17 101 ± 4 5,330 ± 630 0.019 900
W677A 38 ± 3 1.4 ± 0.4 27 3,220 ± 70 103 ± 8 31.2 0.9
S596D/R597M    199 ± 40 12,300 ± 5,000 0.02 
S596D/K602W       
R597M/K602W 2,830 ± 140 3,900 ± 440 0.73 819 ± 129 18,500 ± 4,900 0.044 16
S596D/W677A       
R597M/W677A 468 ± 13 3.8 ± 0.4 120 2,040 ± 80 99 ± 14 21 5.7
K602W/W677A 77 ± 3 2.5 ± 0.6 31 370 ± 16 168 ± 22 2.2 14
R597M/K602W/W677A 920 ± 22 87 ± 9 11 1,190 ± 30 162 ± 12 7.3 1.5
8 Amino Acid Sub.         
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Glutamic Acid at Position 598 has a Limited Role in Determining Cofactor Specificity  
 
 Several reductase clones were generated that did not warrant extensive study or 
discussion.  These include a P450 reductase clone containing alanine substituted for 
glutamic acid at position 598, the importance of which was suggested by its semi-
conserved appearance at this position in sequence alignments with similar NADPH-
specific enzymes (Fig. 1.10).    This mutation lowered the Km by approximately one-half 
with both NADPH and NADH in cytochrome c reductase assays (Table 3.2) when 
compared to wild-type P450 reductase.  When combined with the Ser596Asp mutation 
a similar decrease in Km with both nucleotides was seen compared to the Ser596Asp 
alone.  The kcat values of Glu598Ala and the Ser596Asp/Glu598Ala reductases were not 
considered statistically different from wild-type or Ser598Asp, respectively, with either 
nucleotide.  The modest overall degree of change seen with the Km values and lack of a 
significant effect on kcat values, coupled with the fact that similar effects were seen with 
both NADPH and NADH, suggested a limited role for the glutamic acid 598 in 
influencing cofactor specificity.  A triple mutant reductase containing Ser596Asp, 
Arg597Met and Trp677Ala substitutions was also generated.  However, consistent with 
other reductases containing the Ser596Asp substitution, this protein had negligible 
ability to reduce cytochrome c with either nucleotide cofactor. 
 
TABLE 3.2 Catalytic activities of P450 reductases containing the Glu598Ala 
substitution.  The values represent best fits ± S.D. 
 
Mutant Km (µM) kcat (min-1) Km (µM) kcat (min-1)
WT 1.6 ± 0.1 3,280 ± 50 27,600 ± 4,600 1,210 ± 140
E598A 0.8 ± 0.2 2,390 ± 90 13,200 ± 2,200 1,250 ± 110
S596D 20,600 ± 2,000 140 ± 9 10,100 ± 1,300 101 ± 6
S596D/E598A 9,300 ± 1,800 176 ± 16 5,900 ± 2300 62 ± 9
                      NADPH                                 NADH          
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CHAPTER FOUR 
INHIBITION OF P450 REDUCTASE MUTANTS BY NADP+ 
 
NADP+ as an Inhibitor of Cytochrome c Reductase Activity  
 
 As demonstrated by Döhr et al. (Dohr, Paine et al. 2001), substitution of the 
penultimate amino acid in P450 reductase with alanine (W677A) produces a reductase 
with 1000-fold higher specificity for NADH than NADPH.  Despite this remarkable 
increase in turnover with NADH, the most striking feature of the W677A mutant is that it 
is highly inhibited by NADP+ (Dohr, Paine et al. 2001).  This inhibition is illustrated in 
Figure 4.1 with a W677A mutant I constructed.  The following experiments were 
designed to evaluate the effect of combining 2'-phosphate binding mutations with the 
W677A enzyme on inhibition by NADP+.   Results of these experiments are shown in 
Fig. 4.2. 
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FIGURE 4.1 Inhibition of W677A Reductase by NADPH.  Graph indicates 
enzymatic activity of wild-type and W677A reductases with cytochrome c. 
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NADP+ Inhibition Experiments 
 
 Assays were carried out in 100 mM Tris (pH 8.0), 0.75 M ionic strength with KCl, 
60 µM cytochrome c, and varying concentrations of NADP+.  Reactions were carried out 
for 90 seconds and were monitored on a Hewlett Packard 8453 diode array 
spectrophotometer.  Reduction of cytochrome c was monitored at 550 nm using a 
millimolar extinction coefficient of 21.1 mM-1. 
 
NADP+ Inhibition Results  
 
 The mutations in the phosphate-binding region described in Chapter 3 were 
combined with the W677A substitution in order to overcome the profound inhibition by 
NADP+.  I combined the S596D, R597M, and K602W mutants, as well as the 
R597M/K602W double mutant, with W677A.  Consistent with the other S596D mutants, 
S596D/W677A produced a reductase with little or no activity with either cofactor.  
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However, the R597M/W677A, K602W/W677A, and R597M/K602W/W677A proteins 
were active and displayed reduced catalytic efficiency with NADPH as compared to 
wild-type and increased catalytic efficiency with NADH (Table 3.1).  Of these three 
proteins, the triple mutant (R597M/K602W/W677A) showed a 30,000-fold change in 
cofactor specificity (catalytic efficiency).  Inhibition of cytochrome c reduction by NADP+ 
was determined with these proteins and compared to that of wild-type reductase (Fig. 
4.2).  With the W677A protein, inhibition by NADP+ increased approximately 125-fold, 
from an IC50 of 17.4 µM (wild-type) to an IC50 of 138.3 nM.  Addition of the R597M 
mutation to the W677A protein returned inhibition by NADP+ to a level comparable to 
wild-type reductase.  Inhibition by NADP+ was greatly decreased in the 
R597M/K602W/W677A protein to an IC50 of 870 µM, 50-fold higher than the IC50 for 
wild-type reductase.    
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FIGURE 4.2 Reversal of inhibition by NADP+.  P450 reductase reactions were 
carried out with cytochrome c as described. 
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NADP+ Inhibition Reversed 
 
 The results of experiments outlined here characterize the inhibition by NADP+, a 
product of wild-type P450 reductase catalysis. A reductase useful for in vivo 
applications should retain maximal activity in a mixed-nucleotide environment (NADPH 
and NADH).  The W677A substitution creates a reductase strongly activated by NADH, 
but inhibited by NADP+ at a concentration two orders of magnitude lower than the wild-
type reductase.  The additional substitution of arginine to methionine at position 597 
lowers inhibition to that seen with the wild-type reductase, indicating that the binding of 
the 2'-phosphate of NADPH is an important component for NADP+-mediated inhibition.  
The double substitution protein (R597M and K602W) is inhibited by millimolar 
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concentrations of NADP+, a level much greater than wild-type, further emphasizing the 
importance of phosphate-binding residues in cofactor specificity.    
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CHAPTER FIVE 
ACTIVITY ANALYSIS OF CYTOCHROME P450 REDUCTASE MUTANT PROTEINS 
WITH SQUALENE MONOOXYGENASE AND P450 1A2 
 
Activity of P450 Reductase Proteins with Physiological Redox Partners 
 
 Cytochrome c is an ideal substrate, as discussed in Chapter Two, for monitoring 
the kinetic activity of P450 reductase in vitro.  However, cytochrome c is not a 
physiological redox partner for the reductase.  In fact, cytochrome c is proposed to have 
a different binding site on P450 reductase than the cytochrome P450s (Shen and 
Kasper 1995).  Assays utilizing physiological redox partners were needed to show that 
activities of cofactor substitution mutants characterized by cytochrome c are not unique 
to that substrate.   
 
 Squalene monooxygenase is an FAD-containing protein that catalyzes the 
addition of an oxygen atom across the 2,3-double bond of squalene, a linear 30-carbon 
intermediate in the cholesterol biosynthesis pathway, and is dependent on P450 
reductase for reducing equivalents.  The product of the reaction is 2,3-oxidosqualene, 
which can be separated from squalene by thin layer chromatography and radiolabel 
visualized by electronic autoradiography.  Cytochrome P450 1A2, with reducing 
equivalents from P450 reductase, catalyzes the O-deethylation of ethoxyresorufin to 
resorufin.  Resorufin is a highly fluorescent molecule and its formation can be monitored 
by fluorescence spectroscopy. 
   
Squalene Monooxygenase Assays 
 
 Squalene monooxygenase assays were carried out as described (Laden, Tang et 
al. 2000) based on the method of Bai and Prestwich (Bai and Prestwich 1992).  
Reactions contained 20 mM Tris-HCl (pH 7.4), 0.1% Triton X-100, 30 µM FAD, 1mM 
NADPH, 28 pmols of cytochrome P450 reductase, and 19 pmols of squalene 
monooxygenase in 200 µL total volume.  Incubations were started by the addition of 8 
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nmols of C14-labeled squalene and were carried out for 30 minutes at 37°C.  Reactions 
were stopped by extraction into methylene chloride and separated by thin layer 
chromatography on silica plates (Whatman) in 5% ethyl acetate in hexane.  Plates were 
counted by electronic autoradiography on a Packard Instant Imager. 
  
Cytochrome P450 1A2 Assay:  Ethoxyresorufin O-deethylase Activity (EROD) 
 
 Purified human P450 1A2 was obtained from Oxford Biomedical and activity was 
determined by measuring deethylation of ethoxyresorufin (Sigma) to resorufin, as 
described (Burke and Mayer 1974).  Incubation mixtures (2 ml) contained 2 µM 
ethoxyresorufin, 42 pmols of P450 1A2, 40 pmols reductase, 1 mM NADPH and/or 
NADH, and 0.1 µg/µl of phosphatidylcholine in 100 mM potassium phosphate buffer, pH 
7.7.  Following a 5-min preincubation at 37°C, reactions were started by the addition of 
cofactor and resorufin fluorescence was recorded for 15 minutes with an excitation 
wavelength of 510 nm and an emission wavelength of 586 nm.  Turnover rates were 
calculated from linear time points. 
 
P450 Reductase Mutants Activate Physiological Redox Partners 
 
 I determined the ability of the wild-type and three mutant proteins to support 
squalene monooxygenase activity with both NADPH and NADH (Fig. 5.1).  Consistent 
with the results obtained with cytochrome c, the W677A protein showed limited activity 
with NADPH, having only ~13% of the activity of wild-type reductase.  The addition of 
the R597M substitution to the W677A protein restored full activity with NADPH, while 
the further addition of the K602W substitution (R597M/K602W/W677A) reduced activity 
with NADPH to approximately 28% of wild-type activity.  With NADH, the wild-type 
reductase supported squalene monooxygenase only poorly, and the W677A protein 
was only slightly more active.  However, the double and triple mutants were 2.7- and 
2.3-fold more active with NADH than the W677A mutant. 
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FIGURE 5.1 Activation of squalene monooxygenase by reductase mutants.  
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 Cytochrome P450 1A2 catalyzes the O-deethylation of ethoxyresorufin, and the 
sensitivity of this assay made it ideal for further evaluation of reductase mutations.  The 
results of these experiments are shown in Fig. 5.2.  All mutant proteins showed 
significantly lower deethylase activity with NADPH than wild-type.  With NADH all the 
mutants showed similar activity, roughly twice the activity of wild-type with NADH.  To 
explore how these mutants might fare in a mixed cofactor environment, we determined 
EROD activity with equal concentrations of NADPH and NADH (1 mM).  The W677A 
reductase exhibited only 3.5% of wild-type activity, despite the presence of ample 
NADH, indicating a marked inhibition by NADP+.  In contrast, the R597M/W677A and 
R597M/K602W/W677A proteins showed activity levels approaching those seen with 
NADPH or NADH alone, indication that inhibition by NADP+ was not a factor. 
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FIGURE 5.2 O-deethylation of ethoxyresorufin by CYP 1A2 and P450 reductase 
mutants. 
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CHAPTER SIX 
ACTIVITY ANALYSIS OF CYTOCHROME P450 REDUCTASE MUTANTS IN A 
RECOMBINANT AMES TEST 
 
The Recombinant Ames Assay 
 
 The traditional Ames assay, depicted in Fig. 6.1, is a valuable tool for screening 
compounds which might be capable of causing mutations to DNA.  The assay utilizes 
Salmonella typhimurium strains that are incapable of growth in media lacking histidine.  
This is due to a mutation in several genes necessary for the biosynthesis of histidine 
(Venitt and Parry 1984).  These mutations are, depending on the strain, frameshifts or 
base pair substitutions.  Reversion mutations which restore the ability to synthesize 
histidine are caused by DNA damaging chemicals.  Because many compounds must be 
metabolized to their mutagenic form, mammalian enzymes must be added to the Ames 
test.  The traditional Ames assay typically utilizes a rat liver homogenate (S9 fraction) 
for bioactivation of compounds.  The make-up of this homogenate is typically poorly 
characterized and contains a mixture of enzymes normally present in rat liver.  One 
limitation of the traditional Ames test is false negative results; e.g. when a chemical 
such as dimethylnitrosamine, which is a known human carcinogen, fails to generate a 
positive Ames test.  This may be due to either to lack of the appropriate activating 
enzyme in the S9 or to DNA repair in tester bacteria.  To address the first possibility 
recombinant plasmids which carry the cDNAs for expression of mammalian 
metabolizing enzymes (CYP 2E1 and P450 reductase) were constructed (Porter and 
Chang 1999), see Fig. 6.2; CYP 2E1 is believed to be the primary activator of 
dimethylnitrosamine, in vivo.  However, cells transformed with a plasmid coexpressing 
CYP2E1 and P450 reductase failed to generate a positive Ames test (Cooper and 
Porter 2000).  To address the possibility that the dimethylnitrosamine-induced mutations 
were being repaired, further studies were carried out in strains of S. typhimurium which 
lack, due to chromosomal deletion, one or both of the O6-methylguanine DNA 
methyltransferase genes ogtST and adaST (YG7104 ogt- and YG7108 ogt-, ada-) 
(Yamada, Matsui et al. 1997).  With these strains and expression plasmid, a 
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recombinant Ames test which is sensitive to dimethylnitrosamine was developed 
(Cooper and Porter 2000).  This system allowed me to explore properties of P450 
reductases that are able to utilize NADH in an “in vivo” setting.  Furthermore, I could test 
the hypothesis that NADPH levels limit turnover of P450 reductase in vivo. 
 
FIGURE 6.1 Traditional Ames assay. 
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The Recombinant Ames Assay:  Materials and Procedures  
 
 The activation of dimethylnitrosamine in Salmonella typhimurium strain YG7108 
was carried out as described (Cooper and Porter 2000) with pIN3ER plasmids 
expressing human cytochrome P450 2E1 and either wild-type rat cytochrome P450 
reductase or the R597M/W677A, or R597M/K602W/W677A mutant proteins.  Single 
colonies obtained from electroporation of pIN3ER WT and mutant plasmids were used 
to inoculate overnight cultures in LB media 100 µg/mL ampicillin with IPTG-mediated 
induction of protein expression.  Cells were mixed with increasing concentrations of 
49 
dimethylnitrosamine in top agar and plated onto histidine-deficient Vogel-Bonner plates.  
After incubation for 48 hours at 37°C, visible colonies were counted. 
 
FIGURE 6.2 Recombinant Ames assay. 
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P450 Reductase Proteins Activate P450 2E1 in vivo  
 
 To evaluate the effectiveness of the mutant reductases in vivo, each was 
coexpressed with cytochrome P450 2E1 in Salmonella typhimurium mutagenicity tester 
strains.  The number of revertants generated with dimethylnitrosamine, a mutagenic 
substrate activated by P450 2E1, was determined with each reductase protein (Fig. 
6.3).  Bacteria containing the R597M/W677A reductase yielded nearly twice as many 
revertants as wild-type, suggesting that the improved ability to use NADH increased 
turnover and mutagen activation.  Bacteria containing the R597M/K602W/W677A 
reductase showed very little mutagen activation, and this was shown to be due to very 
low protein expression (Fig. 6.4). 
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FIGURE 6.3 Activation of dimethylnitrosamine by CYP 2E1 and reductase 
proteins, in vivo.  WT, wild-type; RM/WA, Arg597Met/Trp677Ala; RM/KW/WA, 
Arg597Met/Lys602Trp/Trp677Ala.   
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FIGURE 6.4 Western blot of P450 reductase WT, RM/WA and RM/KW/WA 
expression in YG7108 Salmonella typhimurium used in a recombinant Ames test.  
Lane 1, affinity purified wild-type reductase; 2, pIN3ER WT whole cell lysate; 3, 
pIN3ER RM/WA; 4, pIN3ER RM/KW/WA.  
 
  
NADH-utilization May Offer an Advantage in the Recombinant Ames Assay 
  
 The Ames tests data presented above suggest that NADPH might be limiting 
under standard laboratory growth conditions, as suggested previously (Shet, Fisher et 
al. 1997).  As shown, the R597M/W677A reductase mutant, which is able to utilize 
NADH in addition to NADPH, roughly doubled the number of revertants compared with 
wild-type.  To further examine this possibility, mechanisms by which bacteria regulate 
oxidized and reduced pools of NADPH and NADH were studied, with the purpose of 
developing ways to modulate levels of reduced nucleotides in bacteria in vivo.  By 
artificially raising or lowering the concentration of reduced NADPH or NADH, the 
question of rate-limitations due to P450 reductase could be studied by further Ames 
tests.    
 
 Living organisms, including bacteria, require reducing equivalents for respiration 
and subsequent production of ATP.  These catabolic reducing equivalents are provided 
primarily by NADH (and FADH2).  Cells also require reducing power for biosynthetic 
reactions.  Electrons for these anabolic reactions are supplied by NADPH.  Bacteria, as 
1            2             3             4 
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with other organisms, have control mechanisms which maintain proper redox balance 
between oxidized and reduced NADPH and NADH pools.  In Salmonella typhimurium, 
redox status is maintained by regulation of input of carbohydrates into glycolysis, which 
ultimately generates NADH, and the pentose phosphate and Entner-Doudoroff 
pathways which generate NADPH. 
 
 The primary source of the hydride for NADPH in mammals comes from the 
pentose phosphate pathway, also known as the hexose monophosphate shunt.  In this 
process, glucose-6-phosphate is converted to ribulose 5-phosphate, producing two 
NADPH for each molecule converted.  Ribulose-5-phosphate is then converted to 
pyruvate and enters the glycolytic (NADH) pathway.  While believed to be an important 
pathway in E. coli, the pentose phosphate pathway probably supplies less than 50% of 
NADPH needs (Csonka and Fraenkel 1977);  Orthner and Pizer similarly found that the 
pentose phosphate pathway is a major user of  glucose (10 - 30%) in E. coli (Orthner 
and Pizer 1974).  While roughly half of necessary NADPH is produced via the pentose 
phosphate pathway, E. coli contain a transhydrogenase capable of transferring 
electrons directly from NADH to NADPH which makes a minor contribution to NADPH 
levels; the remainder of NADPH is produced through an unidentified pathway (Csonka 
and Fraenkel 1977).  The Entner-Doudoroff pathway is present in Salmonella 
typhimurium, as well as E. coli, and is a second pathway from glucose to pyruvate 
during glycolysis that does not generate fructose-6-phosphate, but instead produces 2-
keto-3-deoxy-6-phosphogluconate (KDPG) (Peekhaus and Conway 1998).  The Entner-
Doudoroff pathway shares its first two steps, oxidation of glucose to gluconate and 
phosphorylation to 6-phosphogluconate, with the pentose phosphate pathway in 
bacteria in a process that produces NADPH and is believed to provide an advantage 
during growth in gluconate-rich environments.  Inhibition or upregulation of one of these 
three pathways might provide a suitable mechanism by which the ratio of reduced 
NADPH to NADH could be altered in bacterial cells.  
   
 As my data (Fig. 6.3) suggested that the availability of reduced NADPH might be 
limiting to the wild-type P450 reductase/P450 2E1 system in Salmonella typhimurium 
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under standard laboratory conditions when grown on glucose, means by which the 
oxidized versus reduced NADPH and NADH ratios could be modulated in vivo would be 
valuable tools to evaluate the significance of such a limitation.  The pentose phosphate 
pathway, Entner-Doudoroff pathway, and the NADPH/NADH transhydrogenase are 
contributors to the NADPH pool in Salmonella typhimurium.  6-Amino-nicotinamide is a 
known inhibitor of NAD(P)H dependent enzymes, including what appears to be a 
pseudo-specific block of the oxidative steps of the hexose monophosphate shunt in 
mammals (Kohler, Barrach et al. 1970).  Though this compound would inhibit the 
pentose phosphate pathway and would thereby lower NADPH levels, it would also be 
likely to inhibit all nicotinamide coenzyme utilizing enzymes, including the mutant 
proteins being evaluated, as well as those enzymes necessary for production of the 
nucleotides themselves, and was therefore not used.  KDPG, mentioned above as an 
intermediate of the Entner-Doudoroff pathway, is a bacteriostatic metabolite that can 
inhibit the pentose phosphate pathway at the 6-phosphogluconate dehydrogenase step 
(Fuhrman, Wanken et al. 1998; Peekhaus and Conway 1998) and would also 
presumably lower NADPH levels.  This compound, however, is not readily available 
commercially.  Finally, it was noted that transhydrogenase activity was low in complex 
media, but high on glucose media (Houghton, Fisher et al. 1976).  Gerolimatos and 
Hanson reported that the inhibitor in complex media was likely to be the amino acid 
leucine, which is able to inhibit the transhydrogenase reaction by up to 80% 
(Gerolimatos and Hanson 1978).  Leucine is readily available and can be easily added 
to culture media.  Inhibition of transhydrogenase activity might be expected to lower 
NADPH levels by inhibiting its synthesis from NADH during exponential growth.  On the 
other hand, the use of gluconate in place of glucose as the primary carbohydrate source 
might be expected to increase the NADPH concentration by stimulating the pentose 
phosphate shunt below the rate limiting step of the pentose phosphate pathway (Fig. 
6.5).  In the following experiments, gluconate was added to stimulate the Entner-
Doudoroff/pentose phosphate pathways (Pathways B & C).  Leucine was added as an 
inhibitor of transhydrogenase (Pathway D). 
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FIGURE 6.5 Major pathways of production of NADP(H) reduction in Escherichia 
coli and Salmonella typhimurium (Csonka and Fraenkel 1977; Gerolimatos and 
Hanson 1978; Peekhaus and Conway 1998). 
 
 
Experimental Design 
 
 Ames tests were carried out as described above (Cooper and Porter 2000).  The 
activation of dimethylnitrosamine in Salmonella typhimurium strain YG7108 was carried 
out with pIN3ER plasmids expressing human cytochrome P450 2E1 and either wild-type 
cytochrome P450 reductase or the R597M/W677A protein.  Single colonies obtained 
from electroporation of pIN3ER and mutant plasmid were used to inoculate overnight 
cultures in LB media containing 100 µg/mL ampicillin and IPTG-mediated induction of 
protein expression.  Cells were mixed with increasing concentrations of 
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dimethylnitrosamine in top agar and plated onto histidine-deficient Vogel-Bonner plates.  
Vogel-Bonner plates contained 1% glucose, 1% gluconate, or 1% glucose with 2 mM 
leucine.  After incubation for 48 hours at 37°C, visible colonies were counted. 
 
Results of Reduced Nucleotide Pool Manipulation 
 
 Ames assays were designed to analyze the effects of additions or changes to the 
culture media on mutagen activation by cells containing the mutant reductases.  These 
culture media changes were intended to alter NADH/NADPH cofactor ratios in the cells.  
Gluconate was expected to increase NADPH levels relative to cells grown in glucose, 
whereas leucine was expected to decrease NADPH levels by blocking the 
transhydrogenase reaction.  Media favoring an increase in NADPH over NADH should 
favor the wild-type reductase.  Conversely, media designed to increase the 
NADH/NADPH ratio should favor the R597M/W677A protein versus wild-type, although 
my data with the in vitro experiments suggests that the R597M/W677A mutant should 
be rather insensitive to variation in nucleotide levels, assuming they remain at roughly 
the same total concentration [NADPH+NADH], because this mutant is able to utilize 
both cofactors at roughly the same efficiency.  Consistent with expectations, with wild-
type reductase gluconate slightly increased mutagenicity of DMN, whereas the addition 
of leucine to the medium slightly decreased mutagenicity (Fig. 6.6).  However, the 
extent of the increase or decrease in mutagenicity was very small and not statistically 
significant, as indicated by the overlapping error bars.  These results indicate that the 
effects of these media modifications on cofactor levels are likely to be small and easily 
compensated in the cells.  
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FIGURE 6.6 Comparison of wild-type reductase activity in Ames assays cultured 
on an array of substrates 
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 Unexpectedly, cells containing the R597M/W677A reductase mutant maintained 
a higher rate of mutagen activation in the presence of gluconate, despite the 
expectation that increased NADPH levels would not favor this enzyme.  Indeed, DMN 
activation in gluconate media was greater than that obtained in glucose media.  These 
results suggest that gluconate may simply increase reduced cofactor levels available to 
the enzyme, and thereby increase overall activity.  DMN activation in the presence of 
leucine was essentially unchanged from that obtained in glucose media, arguing that 
preventing NADPH generation by the transhydrogenase pathway does not impair the 
activity of the R597M/W677A reductase mutant (Fig. 6.7).  This would further suggest 
that the elevated activation of DMN in these cells, relative to cells containing wild-type 
reductase, can be attributed to the greater ability of the R597M/W677A reductase to use 
the more abundant NADH cofactor. It should be noted, however, that cofactor 
levels/ratios were not measured in these cells.   
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FIGURE 6.7 Comparison of R597M/W677A reductase activity in Ames assays 
cultured on an array of substrates 
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 Western blotting of P450 reductase shows qualitatively that the wild-type 
reductase is expressed at a slightly higher level than the R597M/W677A protein (Fig. 
6.8); sodium dodecyl sulfate-polyacrylamide gel electrophoresis shows equal protein 
loading.  As all recombinant Ames assays show revertants with the RM/WA protein at a 
level roughly double that seen with the wild-type enzyme, this increase in DMN 
activation with the R597M/W677A reductase cannot be attributed to higher expression 
levels of this mutant protein, but rather must be an intrinsic characteristic of this protein.  
This is even more surprising given the generally lower activity of this protein when 
purified and assayed in vitro, as noted in the earlier studies (Chapters 3 and 5).   
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FIGURE 6.8 Sodium dodecyl sulfate – polyacrylamide gel electrophoresis (Lanes 
1 & 2) and Western blot (Lanes 3 & 4) of YG7108 Salmonella typhimurium tester 
strains expressing reductases proteins.  Lane 1 & 3, wild-type reductase; 2 & 4, 
R597M/W677A.  
 
 
Cytochrome c Assays with Ames Test Salmonella typhimurium Cell Lysates 
 
 In agreement with this blot data, cytochrome c reductase activities were 
measured with whole cell lysates of YG7108 Salmonella tester cells containing wild-type 
or the R597M/W677A reductase and indicate lower activity with the R597M/W677A 
reductase than with wild-type (Fig. 6.9).  Assays were carried out in 100 mM Tris (pH 
8.0), 0.75 mM ionic strength with KCl, 30 µM cytochrome c and 45 µg of total whole cell 
lysate protein.  Reactions were started by addition of 1 mM nucleotide or a combination 
of 1mM for both nucleotides, and were carried out for 60 seconds and were monitored 
on a Hewlett Packard 8453 diode array spectrophotometer.  The total reduction of 
cytochrome c was monitored at 550 nm using a millimolar extinction coefficient of 21.1 
mM-1 for one minute at room temperature.   
 
    1        2          3       4 
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FIGURE 6.9 Cytochrome c reductase activities of YG7108 Salmonella 
typhimurium cell lysates coexpressing cytochrome P450 2E1 and wild-type or 
mutant reductases.   
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 As with the blotting data (Fig. 6.8), the lower cytochrome c reductase activity of 
the R597M/W677A reductase mutant relative to wild-type reductase in vitro is in marked 
contrast to the mutagenicity data obtained in vivo.  Although various explanations are 
possible, one possibility consistent with all available data is that NADH is significantly 
more abundant than NADPH in bacterial cells, and thus the R597M/W677A reductase, 
with a 2-fold greater kcat and 500-fold greater catalytic efficiency with NADH than the 
wild-type enzyme, has significantly greater activity in this in vivo setting. 
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CHAPTER SEVEN 
CONCLUSIONS 
 
Nucleotide-specificity of P450 Reductase 
 
 Cytochrome P450 reductase has a 45,000-fold preference for NADPH over 
NADH, although the two cofactors differ only in the presence of a 2'-phosphate group on 
the adenine-ribose of NADPH.  The three-dimensional structure of P450 reductase 
revealed three amino acids that interact with this phosphate:  serine 596, arginine 597, 
and lysine 602 (Wang, Roberts et al. 1997) and it is assumed that these amino acids 
dictate the specificity for NADPH.  Consistent with this prediction, Sem and Kasper 
(Sem and Kasper 1993) showed that substitution of a methionine for the positively 
charged arginine at position 597 produces a reductase with impaired ability to 
differentiate between the two cofactors.  The studies presented here support this role for 
arginine 597, and demonstrate that substitution of lysine 602 leads to a further loss in 
specificity for NADPH.  Of the four amino acids examined in this study, these two have 
the greatest influence on NADPH specificity: when combined these substitutions 
increase the Km for NADPH by 2,400-fold.  The effect of these two substitutions on the 
Km for NADH was less predictable:  although both decreased the Km individually 
(R597M 2-fold and K602W 5-fold), when combined the decrease was only about 1.5-
fold.  Moreover, the K602W mutation greatly decreased turnover with NADH.  It is 
unclear why the substitution of tryptophan at this position should have such a 
detrimental effect on NADH-dependent activity, as sequence alignments suggest that a 
tryptophan is found at this position in NADH-specific enzymes (Fig. 1.10).  Given the 
ambiguity in the alignments of the NADH-specific proteins in this region, it is possible 
that substitutions other than tryptophan at this position might more readily 
accommodate NADH binding and turnover. 
 
 Work by Scrutton and Perham (Scrutton, Berry et al. 1990; Bocanegra, Scrutton 
et al. 1993; Mittl, Berry et al. 1993) on the conversion of glutathione reductase to an 
NADH-specific enzyme suggested that an acidic residue opposite the adenine-ribose 
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hydroxyls should enhance the binding of NADH.  This position is occupied by serine 596 
in P450 reductase (Fig. 1.10).  Consistent with this hypothesis, several NADH-specific 
reductases, including cytochrome b5 reductase, contain an aspartate at this position.  
We generated the corresponding mutant in P450 reductase (S596D) but the resulting 
protein exhibited poor turnover with both NADH and NADPH.  Although it was 
anticipated that a negatively charged amino acid at this position would strongly oppose 
NADPH binding by repelling the 2'-phosphate (and indeed, the Km for NADPH increased 
by over 20,000-fold), the marked decrease in kcat with NADH was not expected.  
Although the Km for NADH decreased by greater than half, it was not enough to 
overcome the 90% decrease in catalytic activity.  The incorporation of additional 
mutations in the 2'-phosphate-binding site (R597M, K602W) or the W677A mutation did 
not restore activity with either cofactor, suggesting that the S596D substitution disrupted 
the structure of the cofactor-binding pocket.  Thus, like the K602W mutation, the 
substitution of an “NADH-specific” amino acid at this position had the expected effect on 
activity with NADPH but did not enhance activity with NADH. 
 
 Gutierrez et al. (Gutierrez, Doehr et al. 2000) reported that, in contrast to native 
P450 reductase,  a stable enzyme-NADP+ complex could be formed with a reductase in 
which histidine is substituted for tryptophan 677.  This tryptophan lies directly opposite 
the FAD isoalloxazine ring and is suggested to serve as a gating mechanism for 
cofactor binding.  In support of this idea, movement of the tryptophan is seen during 
NADP(H) binding and release (Gutierrez, Paine et al. 2002).  Loss or substitution of this 
tryptophan should enhance the binding of both NADH and NADPH, and indeed a 
remarkable increase in turnover with NADH is seen in W677 mutants (Dohr, Paine et al. 
2001).  However, turnover with NADPH is greatly decreased, apparently due to 
formation of this stable enzyme-NADP+ complex.  Second-site mutations that decrease 
the affinity of the enzyme for NADP(H) would be expected to decrease the stability of 
the enzyme-NADP+ complex and decrease the inhibition by NADP+.  Consistent with 
this expectation, the R597M/W677A and R597M/K602W/W677A proteins were inhibited 
only at high NADP+ concentrations, and retained good activity in the presence of both 
cofactors in an in vitro P450 assay. 
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 Wild-type P450 reductase is evolutionarily designed to exclusively bind NADPH.  
Gluconate was added as a substrate to increase the NADPH/NADH ratio in Salmonella 
typhimurium during Ames tests.  Wild-type reductase showed higher activation of DMN 
on gluconate in agreement with an increase in reduced NADPH levels versus glucose.  
The amino acid leucine was added to decrease the ratio of NADPH to NADH through 
inhibition of the transhydrogenase.   Consistent with this hypothesis, wild-type P450 
reductase showed reduced ability to activate DMN in the presence of leucine.  The 
R597M/W677A protein, which showed strong NADH-dependent activity in vitro, 
produced a more sensitive Ames test, presumably due to a greater ability to utilize 
NADH for cytochrome P450 2E1-mediated activation of dimethylnitrosamine.  However, 
the R597M/W677A protein also showed high activity with gluconate, a media designed 
to increase the NADPH/NADH ratio.  Though unexpected, these data do not exclude 
the possibility that NADH utilization provides the R597M/W677A proteins superior 
activity in vivo.   
 
Future Studies with P450 Reductase Proteins 
 
 Although I have identified mutations that enhanced the ability of P450 reductase 
to use NADH in the presence of NADPH, I did not create a reductase that is more 
efficient with NADH than NADPH.  Even with the best mutants (R597M/W677A and 
R597M/K602W/W677A), the catalytic efficiency values (kcat/Km) for NADPH and NADH 
were, at best, equivalent.  Thus it remains unclear how to engineer a P450 reductase to 
preferentially use NADH.  Notably, a number of NADH-utilizing enzymes exhibit a 
preference for NADH over NADPH; for example, turnover with NADPH in NADH-
dependent E. coli dihydrolipoamide dehydrogenase is undetectable (Bocanegra, 
Scrutton et al. 1993).  Sequence comparisons of the cofactor-binding region of this 
protein to P450 reductase do not reveal obvious differences that might explain the 
greater selectivity of the dehydrogenase for NADH.  Further biochemical and perhaps 
biophysical studies on P450 reductase will be needed to identify the additional changes 
needed to enhance selectivity for NADH.  “Second-generation” mutants, based on the 
results of present studies, might be more effective.  For example, substitution of aspartic 
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or glutamic acid for arginine 597, rather than methionine as was done in the present 
studies, might promote binding of NADH; the uncharged methionine residue reduced 
the catalytic efficiency with NADPH by 100-fold, but only increased the efficiency with 
NADH by 2-fold.  The alignment data with NADH-specific enzymes suggests that an 
acidic amino acid in this segment is necessary for efficient NADH binding, but the exact 
location is unclear.  In my studies, an acidic amino acid was incorporated at the position 
immediately preceding Arg597, but this substitution (Ser596Asp) yielded a protein with 
little activity with either nucleotide cofactor.  Perhaps the location in 3-dimensional 
space of this acidic residue is critical to function.  A second possible “second-
generation” mutant, replacement of lysine 602 with alanine, rather than tryptophan as 
chosen from sequence alignment, might decrease NADPH-binding without negatively 
influencing interactions with NADH due to a bulky hydrophobic side-chain.   Substitution 
of an acidic side-chain at the 602 position might also improve binding of NADH by 
providing an additional hydrogen bonding residue for the adenine hydroxyl of NADH.    
 
 Site-directed mutagenesis, while a hypothesis-driven technique, limits the 
number of substitutions that may be analyzed.  A technique, such as random 
mutagenesis or gene shuffling, which maximizes the number and types of enzyme 
alterations, might produce a P450 reductase that shows a more profound switch in 
cofactor specificity than those mutants presented here.  Random mutagenesis has been 
used to generate P450 enzymes with altered substrate specificity.  In studies by 
Guengerich and colleagues,  indole was shown to be metabolized by P450 1A2 and 
randomly generated 1A2 mutants coexpressed with P450 reductase in E. coli,  to a 
variety of pigment compounds, including indigo (Nakamura, Martin et al. 2001).  Such a 
screening technique might provide a way to analyze large numbers of randomly 
generated P450 reductase mutants by their ability to stimulate the P450 1A2-mediated 
conversion of indole to indigo.  Perhaps the Ames test might provide an adequate 
screen for sorting the large number of enzymes produced.  One limitation of this screen 
is that it might be difficult to distinguish between NADH-specific and reversion to wild-
type NADPH activity.  Additionally, an Ames assay screen would be expensive due to 
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the large numbers of plates that would be needed to analyze the many mutant proteins 
generated.   
  
 The studies reported here do indicate that it is possible to engineer P450 
reductase for use in vivo by rational design and subsequent evaluation of enzymes in 
vitro.   In addition to providing a valuable tool for understanding the determinants of 
nucleotide cofactor specificity, these mutants might also lend themselves to creation of 
bioremediation with increased enzymatic activity, as well as cost-effective reconstitution 
of enzyme systems that do not require the use of expensive reducing equivalents from 
NADPH.   
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